Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment Highlighting Continued Execution and Strategic Growth
Autonomix Medical (NASDAQ: AMIX) published a new CEO Corner segment on Nov 26, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) published a new CEO Corner segment on Nov 26, 2025.
In the segment, President and CEO Brad Hauser discussed two priorities: protecting the company’s platform via intellectual property, and exploring expansion beyond its initial pancreatic cancer focus into potential cardiovascular, pulmonary, and chronic pain targets.
The segment is available on the company website for investors and stakeholders seeking management commentary on strategy and pipeline direction.
Details
News Market Reaction – AMIX
On Nov 26, the day this news came out, AMIX closed 10.19% above the previous close.
Data tracked by StockTitan Argus for the Nov 26 session.
Historical Context
-
CEO commentary on IP strategy and expansion beyond pancreatic cancer.
-
Dilutive $5.0M private placement with Series C warrants and pre-funded warrants.
-
Post-hoc PoC 1 subgroup results showing sustained QOL improvements in pancreatic cancer.
-
TCT conference podium talks on first-in-human transvascular nerve ablation study.
-
Maxim Growth Summit presentation highlighting nerve-sensing and ablation platform.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pancreatic cancer medical
cardiovascular medical
pulmonary medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
THE WOODLANDS, TX, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the Company’s website. For the segment, Brad Hauser, President and CEO of Autonomix, discussed two key areas that are shaping the Company’s path forward: protecting the strength of its platform through intellectual property, and exploring new opportunities beyond its initial target, pancreatic cancer, into potential future targets in the cardiovascular space, pulmonary space as well as chronic pain.
The CEO Corner segment is now available here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.